The European Union on Thursday approved the highly contentious Alzheimer’s medication Kisunla under strict conditions, with the drug’s effectiveness hotly debated by the medical community.
The European Union on Thursday approved the highly contentious Alzheimer’s medication Kisunla under strict conditions, with the drug’s effectiveness hotly debated by the medical community.